Posts filed under: News

Melbourne (Australia) and Liège (Belgium) – 15 October 2018. Telix Pharmaceuticals Limited announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold...
Continue Reading →
Melbourne (Australia) – 15 October 2018. Telix Pharmaceuticals Limited announced an extension to its master service agreement (MSA) with Cyclotek (Aust) Pty Ltd to include 89Zr-Girentuximab (TLX250-CDx) for imaging patients...
Continue Reading →
Melbourne (Australia) 15 October 2018. Telix Pharmaceuticals Limited announced that it has completed an interim analysis of the ZIR-DOSE dosimetry bridging study, conducted as part of Phase III readiness for...
Continue Reading →
Melbourne and Sydney (Australia) – 10 October 2018. Telix Pharmaceuticals Limited today announced that it has entered into a strategic collaboration agreement with GenesisCare Pty Ltd the largest private provider...
Continue Reading →
Indianapolis IN and Columbus OH (USA) – 3 October 2018. Telix Pharmaceuticals (US) Inc. a subsidiary of Telix Pharmaceuticals Limited, today announced that it has entered into a distribution agreement...
Continue Reading →
Melbourne (Australia) – 11 September 2018. Telix Pharmaceuticals Limited today announced the completion of the acquisition of Atlab Pharma SAS. To facilitate shareholder queries, the Company will be conducting an...
Continue Reading →
Melbourne (Australia) and Nantes (France) – 11 September 2018. Telix Pharmaceuticals Limited today announced the completion of the acquisition of Atlab Pharma SAS. For Market Briefing click here....
Continue Reading →
Melbourne (Australia) and Nantes (France) – 11 September 2018. Telix Pharmaceuticals Limited today announced the completion of the acquisition of Atlab Pharma SAS. The full media release can be accessed here....
Continue Reading →
Melbourne (Australia), Brussels (Belgium) – 4th September 2018. Telix Pharmaceuticals Limited has received ethics approval to commence a Phase I/II study for the use of TLX101 to treat recurrent glioblastoma....
Continue Reading →
Melbourne, Australia, Aug. 31 2018 – Telix Pharmaceuticals Limited is pleased to provide its Half-Year Report 2018, released today. For more information click here – Half Year Report- 30 June 2018...
Continue Reading →